Try our Advanced Search for more refined results

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. March 23, 2021

    Generics MDL Special Master Says Calif. AG Merits Sanctions

    A special master on Monday recommended that the California Attorney General's Office be sanctioned for failing to live up to discovery promises in the sprawling multidistrict litigation that accuses much of the generic drug industry of price-fixing, saying the office should be limited to only evidence that was produced on deadline.

  2. March 17, 2021

    States Push New Bellwether Generic Drug Price-Fixing Case

    If a Pennsylvania federal judge wants to swap out the bellwether case in sprawling litigation that accuses much of the generic drug industry of price-fixing, a coalition of attorneys general want her to choose a different state-brought case than the one she's currently considering as a replacement.

  3. March 02, 2021

    Teva, Mylan Back Plan For New Bellwether In Price-Fix MDL

    Mylan, Teva and Par Pharmaceuticals are among a group of generic-drug makers that told a Pennsylvania federal judge Monday they're fine with her plan to swap out a bellwether case in multidistrict litigation that accuses most of the generics industry of price-fixing.

  4. February 09, 2021

    Teva-Centric Price-Fix Case Likely To Lose Bellwether Status

    A Pennsylvania federal judge said Tuesday she was "no longer convinced" that a price-fixing lawsuit centered around Teva from state attorneys general should serve as a bellwether trial for multidistrict litigation accusing most of the generic-drug industry of price-fixing, thanks to related criminal charges against the company.

  5. January 03, 2021

    Antitrust Conduct Cases To Watch In 2021

    U.S. technology companies are facing a mountain of antitrust litigation heading into 2021, as enforcers push blockbuster monopolization cases against Google and Facebook. Meanwhile, long-running criminal probes in the generic drug and poultry industries are heating up. Here’s a look at the biggest antitrust conduct cases to watch.

  6. November 23, 2020

    Teva's Bid To Duck MDL Trials Slammed As 'Fool's Errand'

    A group of drug buyers and states asked a Pennsylvania federal judge Friday to reject Teva Pharmaceutical's bid to scrap a bellwether trial in multidistrict litigation over civil price-fixing claims to await the outcome of related criminal charges, calling the drugmaker's efforts to keep witnesses from overlapping a "fool's errand."

  7. September 10, 2020

    State AGs Say Drugmakers Want To Delay Price-Fixing Trials

    A contingent of state attorneys general suing generic-drug makers over allegations of price-fixing as part of a sprawling multidistrict litigation have said that drugmakers' proposed schedule for four bellwether cases would delay the first trial for months longer than necessary.

  8. August 27, 2020

    Pa. Avoiding Discovery In Price-Fixing Case, Drugmakers Say

    Generic-drug companies accused of orchestrating an industrywide price-fixing scheme have told a Pennsylvania federal court that the state attorney general's office is refusing to hand over documents they need to help mount a defense.

  9. August 12, 2020

    Resellers Say Drug Makers Erred In MDL Bellwether Claim

    A class of indirect resellers who are accusing a group of generic-drug makers of a price-fixing conspiracy in a multidistrict litigation case told a Pennsylvania federal court the drugmakers incorrectly reviewed the record before accusing the resellers of trying to avoid being among the first cases to go to trial.

  10. August 11, 2020

    Drugmakers Say Resellers Trying To Duck Bellwether Status

    A class of indirect resellers accusing a group of generic-drug makers of a price-fixing conspiracy don't want their cases to proceed to trial first in multidistrict litigation, the drugmakers told a Pennsylvania federal court in a Monday filing.